A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 188
- Population
- ALL · 50 Years
- Duration
- 2021-12-14 to 2027-08-31
- Intervention
- PDS Implant With Ranibizumab 100 mg/ml; LUCENTIS (Ranibizumab Injection)
- Comparator
- Not reported
- Outcomes measured
- Percent Change in Corneal Endothelial Cell Density (ECD) From Baseline at Week 48 in the Study Eye as Compared With the…; Percent Change in Corneal ECD From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye — Baseline, Wee…; Percent Change in the Coefficient of Variation (CV) of Corneal Endothelial Cell Area From Baseline at Weeks 24 and 48 i…; Percent Change in Hexagonal Cells (HEX) From Baseline at Weeks 24 and 48 in the Study Eye as Compared With the Fellow E…; Percentage of Participants With Ocular Serious Adverse Events (SAEs) and Severity of SAEs — Day 1 up to approximately W…; Percentage of Participants With Ocular Adverse Events of Special Interests (AESIs) and Severity of Ocular AESIs — Day 1…; Duration of Ocular AESIs — Day 1 to Week 52; Percentage of Participants With Ocular AESIs During the Postoperative Period — Baseline up to 37 days of initial implan…; Percentage of Participants With Ocular AESIs During the Intermediate Postoperative Period — 38 to 93 days after implant…; Percentage of Participants With Ocular AESIs During the Follow-up Period — Week 52; Percentage of Participants With Adverse Device Effects (ADEs) — Day 1 to Week 52; Number of Participants with Anticipated Serious Adverse Device Effects (ASADEs) and Severity of ASADEs — Day 1 to Week…; Duration of ASADEs — Day 1 to Week 52
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.